{"Q": 1, "answer": "no", "rationale": "'very quickly' modifies the verb 'respond', not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_5184", "batch_size": 200, "batch_pos": 168, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment discusses plans for a human trial and rapid response but contains no Q2 cues.", "method": "llm_batch", "batch_id": "batch_2_19748", "batch_size": 200, "batch_pos": 129, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information. The verb describes a plan.", "method": "llm_batch", "batch_id": "batch_3_2388", "batch_size": 200, "batch_pos": 56, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question present.", "method": "llm_batch", "batch_id": "batch_4_3336", "batch_size": 200, "batch_pos": 47, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports plans and capability ('respond very quickly') but lacks explicit calming language linked to public safety.", "method": "llm_batch", "batch_id": "batch_5_15508", "batch_size": 200, "batch_pos": 42, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_10748", "batch_size": 200, "batch_pos": 2, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "No bare negation present.", "method": "llm_batch", "batch_id": "batch_7_16224", "batch_size": 200, "batch_pos": 185, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes planning a trial and capability: 'could respond very quickly'.", "method": "llm_batch", "batch_id": "batch_8_17784", "batch_size": 200, "batch_pos": 9, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
